1. Home
  2. PRTH vs ALT Comparison

PRTH vs ALT Comparison

Compare PRTH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Priority Technology Holdings Inc.

PRTH

Priority Technology Holdings Inc.

N/A

Current Price

$5.00

Market Cap

451.1M

Sector

Technology

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

N/A

Current Price

$3.60

Market Cap

415.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTH
ALT
Founded
2005
1997
Country
United States
United States
Employees
1019
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
451.1M
415.3M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
PRTH
ALT
Price
$5.00
$3.60
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$8.33
$15.50
AVG Volume (30 Days)
269.5K
2.8M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$10.18
N/A
Revenue Next Year
$9.33
$756,308.50
P/E Ratio
$10.38
N/A
Revenue Growth
N/A
105.00
52 Week Low
$4.44
$2.91
52 Week High
$8.89
$7.73

Technical Indicators

Market Signals
Indicator
PRTH
ALT
Relative Strength Index (RSI) 32.82 34.82
Support Level $4.44 $3.39
Resistance Level $6.01 $4.25
Average True Range (ATR) 0.23 0.24
MACD -0.05 -0.06
Stochastic Oscillator 8.38 13.75

Price Performance

Historical Comparison
PRTH
ALT

About PRTH Priority Technology Holdings Inc.

Priority Technology Holdings Inc is a provider of merchant acquiring and commercial payment solutions to small and medium business enterprises in the United States. The company has three reportable segments which are SMB Payments, B2B Payments, and Enterprise Payments. SMB Payments segment which generates the majority of revenue provides full-service acquiring and payment-enabled solutions for B2C transactions, leveraging Priority's proprietary software platform, distributed through ISO; the B2B Payments segment provides AP automation solutions to corporations, software partners, & industry FIs: and Enterprise Payments segment provides embedded payment & treasury solutions to enterprise customers to modernize legacy platforms & accelerate software partners' strategies to monetize payments.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: